marijuana stocks news

GW Pharmaceuticals to Present at Two Upcoming Investor Conferences

LONDON, Sept. 10, 2015 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt New York on 16 September, 2015 at 4:15 p.m. EDT and Adam George, GW’s Chief Financial Officer is scheduled to present at the Bank of America Merrill Lynch Global Healthcare Conference 2015 at the Bank of America Merrill Lynch office in London, England on 17 September, 2015 at 3:25 p.m. BST.

A live audio webcast of the presentations will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) (CBD or cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Contact:
Enquiries:
GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK)
+ 44 20 3727 1000


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Terra Tech Corp. (TRTC) Schedules Full-Year 2019 Earnings Release for Friday, March 13, 2020

Terra Tech Corp. Schedules Full-Year 2019 Earnings Release for Friday, March 13,…

$CBIS Pleased with CNN Monitoring of The Outcome of State By State Voting for Medical Marijuana Legalization

Cannabis Science Enthused With CNN Monitoring The Outcome Of The National State…

Choom Holdings Inc. (CHOOF) Completes $4,100,000 Convertible Debenture Unit Private Placement

Choom Completes $4,100,000 Convertible Debenture Unit Private Placement Choom Holdings Inc. (the…